October is the month for breast cancer awareness, and there’s been some encouraging news. Although the month began with some critics arguing that the pink ribbon campaign has created a false sense of security that the breast cancer battle is under control – that pink ribbon ubiquity has actually hindered research and progress – a couple of recent studies are encouraging. The Big Pharma disaster, aka HRT (hormone replacement therapy), inflated breast cancer cases. As doctors are now more cautious about recommending and prescribing this course of treatment for women, breast cancer rates have dropped.
But it’s not just breast cancer. Encouragingly, across the board, we’re seeing slight but meaningful drops in some types of cancer, particularly in at-risk groups. A few standouts: lung cancer has dropped a bit in women (women are more at risk to begin with). Colorectal cancers are down in men, largely due to better screening practices.